Igyxos: Igyxos and Selexis Enter Service Agreement to Advance Igyxos' First-In-Class Monoclonal Antibody for the Treatment of Human Infertility

(marketscreener.com) Selexis SA and Igyxos announced today that they have entered into a service agreement to develop Igyxos' first-in-class monoclonal antibody drug candidate for the treatment of human infertility. Under the agreement, Igyxos will utilize Selexis' proprietary SUREtechnology Platform to rapidly develop the research cell banks ...https://www.marketscreener.com/news/Igyxos-and-Selexis-Enter-Service-Agreement-to-Advance-Igyxos-First-In-Class-Monoclonal-Antibody-for--31220489/?utm_medium=RSS&utm_content=20200902